






















Our recent study characterized a role for mitochondrial 
superoxide in the pathology of Alzheimer’s disease [1]. 
Using the Tg2576 Alzheimer's disease (AD) mouse 
model in combination with a mouse that overexpresses 
the mitochondrial antioxidant enzyme superoxide 
dismutase (SOD-2), we showed that severe deficits in 
the spatial and associative memory of AD mice could 
be prevented by scavenging of superoxide. SOD-2 
overexpression also resulted in a reduction in amyloid-β 
(Aβ) plaque deposition without affecting the levels of 
soluble and fibrillar Aβ. It did however lead to a 
reduction in the Aβ 42/40 ratio resulting in an Aβ pool 
composition less favorable for aggregation. These 
findings point towards the involvement of 
mitochondrial superoxide in AD pathology perhaps 
through its effects on Aβ processing. Here we discuss 
these findings and comment on the future directions that 
this research may lead to. 
 
Alzheimer’s disease (AD) is a progressive neuro-
degenerative disease characterized by the neuro-
pathological deposition of extracellular amyloid-β (Aβ) 
plaques and intracellular tau neurofibrillary tangles [2]. 
The disease also is characterized by the devastating loss 
of memory and cognitive functions, which is thought to 
arise from the increased production of Aβ [3]. The 
neurotoxic role of Aβ has long been established [3], 
however, it is not clear how it contributes to the 
cognitive deficits characteristic of AD. In addition to 
Aβ, several studies have implicated oxidative stress in 

























result of overproduction of oxygen free radicals by 
mitochondria. The reactive oxygen species (ROS) 
superoxide is produced by complexes I and III of the 
mitochondrial respiratory chain [4], and is primarily 
detoxified by the mitochondrial antioxidant enzyme 
superoxide dismutase (SOD-2). Many lines of evidence 
support a pro-oxidant role for Aβ during AD [5,6]. Aβ 
promotes the production of ROS in several model 
systems by causing dysfunction of the mitochondrial 
respiratory chain. Despite overwhelming evidence for 
the pro-oxidant role of Aβ, several other studies 
demonstrate ROS involvement prior to amyloid 
pathology [7,8]. Oxidative stress has been shown to 
exacerbate multiple AD phenotypes. For example, 
partial SOD-2 deficiency has been shown to accelerate 
plaque deposition [9] and increase tau phosphorylation 
in AD mice models [10]. SOD-2 deficiency also has 
been shown to accelerate the onset of a number of 
behavioral deficits in hAPP mice [11]. 
 
In our recent study, we investigated the involvement of 
mitochondrial dysfunction in AD pathology by studying 
the offspring of Tg2576 AD model mice that were 
crossed with mice that overexpress SOD-2 [1]. We 
found that the elevated SOD-2 reduced age-dependent 
increases in hippocampal superoxide, presumably from 
mitochondria, in the Tg2576 mice [1]. The reduction of 
hippocampal superoxide in the Tg2576 mice by SOD-2 
overexpression was correlated with the prevention of 
spatial and associative memory deficits, as measured by 
the Morris water maze and fear conditioning tests, 
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and Aβ42 in these mice. Although we observed no 
difference in the absolute levels of these two peptides in 
the Tg2576/SOD-2 mice compared to the Tg2576 mice, 
we found that the ratio of Aβ42 to Aβ40 was reduced by 
the overexpression of SOD-2, which is suggestive of an 
Aβ pool less favorable for aggregation [1]. This notion 
was supported by histological analysis demonstrating 
that overexpression of SOD-2 resulted reduced amyloid 
plaque deposition [1].  
 
Our data are in agreement with several studies that 
demonstrate the involvement of mitochondrial ROS in 
AD [9-12]. These studies specifically link SOD-2 
deficiency with increased AD pathology and reduced 
mitochondrial ROS with improved cognition [9-12]. 
Shortly following the submission of our studies for 
publication, two new supporting studies were published. 
The first one linked α-ketoglutarate dehydrogenase 
enzyme complex deficiency with increased 
mitochondrial ROS production and subsequent 
acceleration of the memory impairments and plaque 
deposition in Tg19959 mice [13]. The second study 
demonstrated mitochondrial ROS involvement in AD 
using a cross between the Tg19959 mouse model of AD 
and the SOD-2 overexpressing mice [14]. In agreement 
with our results, these authors demonstrated that 
memory impairments and increased plaque deposition 
in the Tg19959 mice were both alleviated by 
overexpression of SOD-2 [14]. These authors also 
showed that increased Aβ42 levels in the Tg19959 mice 
were resistant to overexpression of SOD-2 [14]. The 
authors interpreted this data as evidence that the 
facilitation of mitochondrial antioxidant responses 
results in resistance to Aβ and improvement of the 
global AD phenotype [14].  
 
Our findings, together with the aforementioned studies, 
strongly suggest that mitochondrial ROS affect Aβ 
processing. One attractive possibility is the involvement 
of mitochondrial ROS in the assembly of fibrillar Aβ 
into plaques. This notion is supported by us and others, 
showing that quenching ROS does not affect fibrillar 
Aβ levels but reduces plaque deposition. 
 
The involvement of oxidative stress in AD has long 
been known and investigated [5,6,15,16]. As a result of 
multiple studies linking AD to oxidative damage, the 
use of antioxidant therapy for AD has received 
considerable attention over the years. Clinical trials, 
however, have produced conflicting results concerning 
the therapeutic efficacy of antioxidant treatment for AD 
[17,18]. This may be due to either poor understanding 
of the pharmacokinetics or suboptimal specificity of the 
antioxidants compared with targeted pharmacological 
therapy. We and others have shown a specific 
involvement of mitochondrial superoxide in the etiology 
of AD [1,9-11,14]. Therefore designing antioxidants 
targeted towards mitochondrial ROS offers an attractive 
therapeutic approach for AD. An important 
consideration to keep in mind is that the SOD-2 
overexpressing mice likely have reduced levels of 
mitochondrial ROS beginning at birth and hence, 
studying the offspring generated when these mice are 
mated with the Tg2576 AD mice shows that quenching 
mitochondrial superoxide is a preventive approach to 
the occurrence of AD. A more clinically relevant 
approach would be to determine the specific temporal 
window in which removal of mitochondrial ROS is 
most effective.  
 
One could use either genetic or pharmacological 
approaches to determine whether removal of 
mitochondrial ROS reverses rather than prevents 
cognitive deficits in AD model mice. From a genetic 
standpoint, an attractive approach would be to study the 
progeny of Tg2576 AD mice crossed to a mouse that 
could be induced to express SOD-2 on demand (for 
example a mouse that overexpresses SOD-2 in response 
to tetracycline treatment – tet-on-SOD-2). Studying AD 
model mice that could overexpress SOD-2 at any age 
would permit one to determine whether diminishing 
mitochondrial superoxide after the onset of AD 
phenotypes could reverse symptoms of AD, such as 
cognitive dysfunction and plaque deposition.  
 
From a pharmacological standpoint, the design of 
antioxidants specifically targeted to mitochondria to 
quench mitochondrial ROS is necessary. Pharmacolo-
gical catalytic scavengers of superoxide and hydrogen 
peroxide have proven quite effective in reversing age-
related cognitive deficits [19]. In the context of AD, 
these compounds only have been tested in organotypic 
hippocampal cultures treated with Aβ42 or Aβ40 [20]. 
In support of our findings, SOD/catalase mimetics were 
shown to be effective against Aβ-induced neurotoxicity 
[20]. These mimetics, however, are not specific to 
mitochondrial ROS and do not provide information for 
determining the optimal temporal window in vivo for 
treatment of AD. A set of synthetic plastoquinone 
derivatives recently were shown to specifically target 
the mitochondria and act as potent antioxidants at low 
concentrations [21,22] . The antioxidant properties of 
these derivatives (termed SKQs) have been investigated 
in the context of senescence and age-related 
impairments such as blindness [23], ischemia [24], 
stroke [24] and tumor development [25]. Although these 
agents can act as potent pro-oxidants at higher 
concentrations and optimization of the antioxidant 
therapeutic window is necessary [21,22], they appear to 
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treating age-related diseases [21-27]. In the context of 
our data, which show an involvement of mitochondrial 
ROS in AD pathology, the use of the SKQ agents for 
the treatment of AD should be investigated. 
 
In conclusion, our findings have reinforced the idea that 
mitochondrial superoxide plays a critical role in the 
pathological events following Aβ elevation during AD. 
More specifically, we were able to show that increasing 
the expression of the mitochondrial antioxidant enzyme 
SOD-2 prevents memory deficits and amyloid plaque 
deposition associated with AD. Moreover, our findings 
suggest that mitochondrial superoxide may be involved 
in Aβ processing, perhaps at the level of accumulation 
of fibrillar Aβ into plaques. The next challenge will be 
to determine whether quenching mitochondrial 
superoxide, in addition to being preventative, can be 
therapeutic for the treatment and reversal of cognitive 
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